Impact of non-medical cannabis legalization with market restrictions on health service use and incident cases of psychotic disorder in Ontario, Canada.

[1]  M. Solmi,et al.  Association between non-medical cannabis legalization and emergency department visits for cannabis-induced psychosis. , 2023, Molecular psychiatry.

[2]  E. B. Rognli,et al.  Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder. , 2023, The American journal of psychiatry.

[3]  P. Kurdyak,et al.  Amphetamine-Related Emergency Department Visits in Ontario, Canada, 2003-2020 , 2023, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[4]  Ellicott C. Matthay,et al.  State Cannabis Legalization and Psychosis-Related Health Care Utilization , 2023, JAMA network open.

[5]  T. Elton-Marshall,et al.  Changes in health harms due to cannabis following legalisation of non-medical cannabis in Canada in context of cannabis commercialisation: A scoping review. , 2022, Drug and alcohol review.

[6]  D. Devoe,et al.  Trends in Canadian Cannabis Consumption Over Time: A Two-step Meta-analysis of Canadian Household Survey Data , 2022, Canadian Journal of Addiction.

[7]  R. Pacula,et al.  Impact of cannabis legalization on healthcare utilization for psychosis and schizophrenia in Colorado. , 2022, The International journal on drug policy.

[8]  M. Taljaard,et al.  The association between recreational cannabis legalization, commercialization and cannabis attributable emergency department visits in Ontario, Canada: an interrupted time-series analysis. , 2022, Addiction.

[9]  S. Kish,et al.  Associations Between Canada's Cannabis Legalization and Emergency Department Presentations for Transient Cannabis-Induced Psychosis and Schizophrenia Conditions: Ontario and Alberta, 2015–2019 , 2022, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[10]  May Y. Choi,et al.  Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States Submit to: Psychiatry Research , 2022, Psychiatry Research.

[11]  B. Fischer,et al.  An overview of select cannabis use and supply indicators pre- and post-legalization in Canada , 2021, Substance Abuse Treatment, Prevention, and Policy.

[12]  S. Vigod,et al.  Acute mental health service use following onset of the COVID-19 pandemic in Ontario, Canada: a trend analysis , 2021, CMAJ open.

[13]  M. Taljaard,et al.  How has access to legal cannabis changed over time? An analysis of the cannabis retail market in Canada 2 years following the legalisation of recreational cannabis. , 2021, Drug and alcohol review.

[14]  M. Nordentoft,et al.  Mortality in substance-induced psychosis: A register-based national cohort study. , 2021, Addiction.

[15]  M. Rotermann.  Looking back from 2020, how cannabis use and related behaviours changed in Canada. , 2021, Health reports.

[16]  J. Quintin,et al.  The Potential Impact of Recreational Cannabis Legalization on the Prevalence of Cannabis Use Disorder and Psychotic Disorders: A Retrospective Observational Study , 2021, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[17]  D. Hammond,et al.  How High? Trends in Cannabis Use Prior to First Admission to Inpatient Psychiatry in Ontario, Canada, between 2007 and 2017 , 2020, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[18]  S. Wallingford,et al.  Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015. , 2020, Health promotion and chronic disease prevention in Canada : research, policy and practice.

[19]  W. Hall,et al.  Assessing the public health impacts of legalizing recreational cannabis use: the US experience , 2020, World psychiatry : official journal of the World Psychiatric Association.

[20]  Peter B. Jones,et al.  Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study , 2020, Psychological Medicine.

[21]  R. Murray,et al.  Cannabis Use and the Risk for Psychosis and Affective Disorders , 2020, Journal of dual diagnosis.

[22]  M. Large,et al.  Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis , 2019, Schizophrenia bulletin.

[23]  C. Ramsay,et al.  Methodology and reporting characteristics of studies using interrupted time series design in healthcare , 2019, BMC Medical Research Methodology.

[24]  P. Tanuseputro,et al.  Access to cannabis retail stores across Canada 6 months following legalization: a descriptive study. , 2019, CMAJ open.

[25]  Peter B. Jones,et al.  The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study , 2019, The lancet. Psychiatry.

[26]  S. Leatherdale,et al.  Prelegalisation patterns and trends of cannabis use among Canadian youth: results from the COMPASS prospective cohort study , 2019, BMJ Open.

[27]  M. Oremus,et al.  The Effect of Age of Initiation of Cannabis Use on Psychosis, Depression, and Anxiety among Youth under 25 Years , 2018, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[28]  P. Kurdyak,et al.  Estimating the incidence of first-episode psychosis using population-based health administrative data to inform early psychosis intervention services , 2018, Psychological Medicine.

[29]  A. Monte,et al.  Mental Health–related Emergency Department Visits Associated With Cannabis in Colorado , 2018, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[30]  A. Biglan,et al.  Medical Marijuana Legalization and Marijuana Use Among Youth in Oregon , 2017, The Journal of Primary Prevention.

[31]  P. Kurdyak,et al.  The Economic Burden of Chronic Psychotic Disorders in Ontario. , 2016, The journal of mental health policy and economics.

[32]  R. Murray,et al.  Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. , 2016, Schizophrenia bulletin.

[33]  A. Gasparrini,et al.  Interrupted time series regression for the evaluation of public health interventions: a tutorial , 2016, International journal of epidemiology.

[34]  M. Hickman,et al.  Association Between Cannabis and Psychosis: Epidemiologic Evidence , 2016, Biological Psychiatry.

[35]  M. Large,et al.  Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use , 2016, The Australian and New Zealand journal of psychiatry.

[36]  S. Bhattacharyya,et al.  Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. , 2016, Lancet psychiatry.

[37]  L. Smeeth,et al.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement , 2015, PLoS medicine.

[38]  S. Vigod,et al.  Validation of a Population-Based Algorithm to Detect Chronic Psychotic Illness , 2015, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[39]  E. Susser,et al.  Incidence of psychotic disorders among first-generation immigrants and refugees in Ontario , 2015, Canadian Medical Association Journal.

[40]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[41]  H. Morgenstern,et al.  Ecologic studies in epidemiology: concepts, principles, and methods. , 1995, Annual review of public health.